SIGNAL FARMASJUTIKALZ;SIGNAL FARMAS'JUTIKALZ; EHLEHLSI
发明人:
EhL'SNER Jan (US),ЭЛЬСНЕР Ян (US),KhARRIS Roj L. (US),ХАРРИС Рой Л. (US),LI Brehnden (US),ЛИ Брэнден (US),MORTENSEN Debora (US),МОРТЕНСЕН Дебора (US),PAKARD Garrik (US),ПАКАРД Гаррик (US),PAPA Patrik,EHLSNER JAN,ЭЛЬСНЕР Ян,KHARRIS ROJ L.,ХАРРИС Рой Л.,LI BREHNDEN,ЛИ Брэнден,MORTENSEN DEBORA,МОРТЕНСЕН Дебора,PAKARD GARRIK,ПАКАРД Гаррик,PAPA PATRIK,ПАПА Патрик,PERREN-NINKOVICH SOFI,ПЕРРЕН-НИНКОВИЧ С
申请号：
RU2011121353/04
公开号：
RU0002546658C2
申请日:
2009.10.27
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: in general formulas R1 represents substituted phenyl, substituted or unsubstituted heterocyclyl, which represents an aromatic cycloalkyl containing 6 to 10 atoms in the cycle and wherein one to two carbon atoms in the cycle are independently substituted by N, wherein the above substitutes are specified in C1-8alkyl, triazolyl, halogen, aminocarbonyl, cyano or hydroxyalkyl； R2 represents H, substituted or unsubstituted C1-8alkyl, substituted C3-6cycloalkyl, unsubstituted heterocyclyl, which represents non-aromatic cycloalkyl containing 5 to 6 atoms in the cycle and wherein one to two carbon atoms in the cycle are independently substituted by N or O； unsubstituted heteroyclylalkyl, wherein heterocyclyl represents non-aromatic cycloalkyl containing 5 to 6 atoms in the cycle and wherein one to two carbon atoms in the cycle are independently substituted by N and O； substituted or unsubstituted phenylalkyl or substituted or unsubstituted C3-6cycloalkylalkyl, wherein the above substitutes are specified in C1-4alkyl, CF3, OR and NR2, wherein R represents H or C1-4alkyl； each R3 and R4 independently represents H, unsubstituted C1-8 alkyl, or R3 and R4 together with the atom to which they are attached form C3-6cycloalkyl； or R2 and one of R3 and R4 together with the atom to which they are attached form substituted or unsubstituted heterocyclyl containing 5 to 6 atoms in the cycle and which can contain additional heteroatom specified in O； wherein the substitutes are specified in -C(O)CH2OCH3, -CH2CH2OCH3, OCH3 or CH3.EFFECT: invention refers to compounds of formulaand ,a based pharmaceutical composition and to a method of treating or preventing cancer, immunological conditions, diabetes, obesity, neurological disturbances and age-related diseases, a method for mTOR kinase inhibition in a cell, a method of treating or preventing the condition, which can be treated or prevented by mTOR kinase metabolic path inhibition.53 cl, 1 tbl, 20 e
